Apeloa Pharmaceutical (000739.SZ) Obtains European CEP Certificate for Venlafaxine Hydrochloride API

Stock News

11/10

Apeloa Pharmaceutical Co., Ltd. (000739.SZ) announced that its wholly-owned subsidiary, Zhejiang Apeloa Jiayuan Pharmaceutical Co., Ltd., recently received the Certificate of Suitability to the European Pharmacopoeia (CEP) for Venlafaxine Hydrochloride issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM).

Venlafaxine Hydrochloride is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) used to treat various types of depression (including depression with anxiety) and generalized anxiety disorder.

The approval of the CEP certificate for Venlafaxine Hydrochloride API demonstrates recognition of its quality by the regulated European market. This milestone confirms the product's eligibility to enter the EU and other markets that recognize CEP certification in API form, which will positively contribute to the company's further expansion into international markets.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1154494538"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1154494538\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1154494538?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-10 16:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1154494538","market":"fut","top_or_hot":-1,"title":"Apeloa Pharmaceutical (000739.SZ) Obtains European CEP Certificate for Venlafaxine Hydrochloride API","media":"Stock News","content":"<p>Apeloa Pharmaceutical Co., Ltd. (000739.SZ) announced that its wholly-owned subsidiary, Zhejiang Apeloa Jiayuan Pharmaceutical Co., Ltd., recently received the Certificate of Suitability to the European Pharmacopoeia (CEP) for Venlafaxine Hydrochloride issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM).</p>\n<p>Venlafaxine Hydrochloride is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) used to treat various types of depression (including depression with anxiety) and generalized anxiety disorder.</p>\n<p>The approval of the CEP certificate for Venlafaxine Hydrochloride API demonstrates recognition of its quality by the regulated European market. This milestone confirms the product's eligibility to enter the EU and other markets that recognize CEP certification in API form, which will positively contribute to the company's further expansion into international markets.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Apeloa Pharmaceutical (000739.SZ) Obtains European CEP Certificate for Venlafaxine Hydrochloride API</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nApeloa Pharmaceutical (000739.SZ) Obtains European CEP Certificate for Venlafaxine Hydrochloride API\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-10 16:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Apeloa Pharmaceutical Co., Ltd. (000739.SZ) announced that its wholly-owned subsidiary, Zhejiang Apeloa Jiayuan Pharmaceutical Co., Ltd., recently received the Certificate of Suitability to the European Pharmacopoeia (CEP) for Venlafaxine Hydrochloride issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM).</p>\n<p>Venlafaxine Hydrochloride is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) used to treat various types of depression (including depression with anxiety) and generalized anxiety disorder.</p>\n<p>The approval of the CEP certificate for Venlafaxine Hydrochloride API demonstrates recognition of its quality by the regulated European market. This milestone confirms the product's eligibility to enter the EU and other markets that recognize CEP certification in API form, which will positively contribute to the company's further expansion into international markets.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0188","symbol_name":"融资融券","start_time":0,"source_url":"","article_id":"1154494538","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1154494538","pubTimestamp":1762764381,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Apeloa Pharmaceutical Co., Ltd. (000739.SZ) announced that its wholly-owned subsidiary, Zhejiang Apeloa Jiayuan Pharmaceutical Co., Ltd., recently received the Certificate of Suitability to the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK0188":"融资融券","CEP":"Cantor Equity Partners Inc","BK0060":"抗癌","000739":"普洛药业","BK0239":"医药制造"},"translate_title":"Apeloa Pharmaceutical(000739.SZ)获得盐酸文拉法辛原料药欧洲CEP证书","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CEP":1,"000739":1},"content_text":"Apeloa Pharmaceutical Co., Ltd. (000739.SZ) announced that its wholly-owned subsidiary, Zhejiang Apeloa Jiayuan Pharmaceutical Co., Ltd., recently received the Certificate of Suitability to the European Pharmacopoeia (CEP) for Venlafaxine Hydrochloride issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM).\nVenlafaxine Hydrochloride is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) used to treat various types of depression (including depression with anxiety) and generalized anxiety disorder.\nThe approval of the CEP certificate for Venlafaxine Hydrochloride API demonstrates recognition of its quality by the regulated European market. This milestone confirms the product's eligibility to enter the EU and other markets that recognize CEP certification in API form, which will positively contribute to the company's further expansion into international markets.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}